News
An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...
After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...
The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...
5d
MedPage Today on MSNMRI Leaves Man in Critical Condition; Dexcom Recall After 56 Injuries; Drug DenialsNote that some links may require registration or subscription. A New York man who entered an MRI room while a scan was taking ...
Hosted on MSN29d
Hims & Hers stock plummets after Novo Nordisk ends partnership over ‘knockoff’ WegovyOther telehealth companies, like Ro and Noom, have similarly faced criticism for continuing to sell their own compounded GLP-1 medications despite agreements with Eli Lilly, the maker ... “Based on ...
Earlier versions of a spending cuts package targeted PEPFAR, the popular global AIDS relief program. The White House agreed to spare the program to avoid defections, and the spending cuts passed the ...
A High Rate of Prescriptions Are Written. The Report examined the number of prescriptions that resulted from patient participation in a Program, concluding that the rate was “high”. In one case, the ...
Eli Lilly and Company's recovery has not regained fervor as the digestion over its high-growth premium continues. Learn more about LLY stock here.
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent implosion of Novo’s partnership with telehealth firm Hims & Hers suggests ...
US Senators are concerned that Pfizer and Eli Lilly's recent forays into direct-to-consumer distribution of medicines via telehealth platforms could violate federal anti-kickback laws. The four ...
Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...
Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I initiate a Buy rating on LLY stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results